Zai Lab Announces First Patient Treated in Greater China Portion of Potentially Registrational, Global Phase 2 Study of Odronextamab
October 25, 2021 07:30 ET
|
Zai Lab Limited
SHANGHAI and SAN FRANCISCO and CAMBRIDGE, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global...
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
August 31, 2020 20:54 ET
|
Bragar Eagel & Squire
NEW YORK, Aug. 31, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regeneron, Inc. (NASDAQ:...
BioNTech gibt Kollaboration mit Regeneron zur Entwicklung einer Melanom-Kombinationstherapie aus FixVac und Libtayo® (Cemiplimab) bekannt
July 31, 2020 02:00 ET
|
BioNTech SE
BioNTech und Regeneron planen die gemeinsame Durchführung einer randomisierten Phase-2-Studie mit einer Kombination aus FixVac BNT111 und Libtayo für die Behandlung von maligem Melanom (schwarzer...
BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and Libtayo® (cemiplimab) Combination in Melanoma
July 31, 2020 02:00 ET
|
BioNTech SE
BioNTech and Regeneron plan to jointly conduct a randomized Phase 2 study combining BNT111 FixVac and Libtayo for the treatment of melanoma that has progressed after prior PD-1 blockadeCombines two...
Scott+Scott Attorneys at Law LLP Investigates Regeneron Pharmaceuticals, Inc.’s Directors and Officers for Breach of Fiduciary Duty – REGN
July 01, 2020 11:27 ET
|
Scott+Scott Attorneys at Law LLP
NEW YORK, July 01, 2020 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, is investigating whether certain directors...
KYMAB WINS SUPREME COURT CASE AGAINST REGENERON
June 24, 2020 05:29 ET
|
Kymab Group Ltd
KYMAB WINS SUPREME COURT CASE AGAINST REGENERON Landmark UK Supreme Court Decision Invalidates Regeneron Patent Claims Cambridge, UK; 24 June, 2020: Kymab, a clinical-stage biopharmaceutical company...
Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc.; Raises Price Target to $14.00
July 31, 2013 09:15 ET
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwired - Jul 31, 2013) - Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (NASDAQ: OHRP) ("The Company" or "OHR") and raised its...
Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc.; Target Price $3.50
October 17, 2012 09:15 ET
|
Vista Partners LLC
SAN FRANCISCO, CA--(Marketwire - Oct 17, 2012) - Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (OTCBB: OHRP) ("The Company" or "OHR") with a twelve month...
Vista Partners Updates Coverage on Ohr Pharmaceutical, Inc.; Raises Target Price to $3.50
August 01, 2012 09:15 ET
|
Vista Partners
SAN FRANCISCO, CA--(Marketwire - Aug 1, 2012) - Vista Partners announced today that it has updated coverage on Ohr Pharmaceutical, Inc. (OTCBB: OHRP) ("The Company" or "OHR") and raised its...